Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

Tongji University, Shanghai Pulmonary Hospital, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, Jiangsu Cancer Hospital, Academy of Military Medical Sciences, Tianjin Medical University Cancer Institute and Hospital, Capital Medical University, Beijing Chest Hospital, Peking University, Peking University Cancer Hospital, Shanghai Jiao Tong University, Shanghai Chest Hospital, Sun Yat-sen University, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Sun Yat-sen University Cancer Center, Central South University, Second Xiangya Hospital of Central South University, Xiangya Hospital Central South University, Hunan Cancer Hospital, Shantou University, Cancer Hospital of Shantou University Medical College, Renji Hospital, Soochow University, First Affiliated Hospital of Soochow University, Zhejiang Cancer Hospital, Second Military Medical University, Harbin Institute of Petroleum, Nanfang Hospital, Southern Medical University